Oelschlager Kristen M sold $256K of CSTL

Oelschlager Kristen M (Chief Operating Officer) sold 8,586 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $29.77 ($29.12–$30.62, $0.26M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Oelschlager Kristen M
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The COO’s scheduled open-market sale reduces insider holdings but does not, by itself, indicate new negative fundamentals given the stated 10b5-1 pre-arranged plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks new operational or financial information.

03

What to watch

The article does not disclose any change in business outlook, guidance, or risk events; without those, the trading signal is mostly sentiment and positioning rather than fundamentals.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, sale executed 2026-08-03

Background

The article is a primary-source SEC Form 4 insider transaction for CASTLE BIOSCIENCES (CSTL).

Company-level read

Ticker impact

$CSTLNeutralMedium confidence
Context

CASTLE BIOSCIENCES COO Kristen M Oelschlager sold $255,622 of CSTL shares via a 10b5-1 plan on 2026-08-03.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or financial catalyst in the text.

Market effects

No sector-wide implications are stated; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.

Key entities

  • CASTLE BIOSCIENCES INC

    Company whose insider transaction is disclosed on SEC Form 4.

  • Kristen M Oelschlager

    Chief Operating Officer who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CSTLMed

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

$CSTLMed

Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

$CSTLHigh

Castle Biosciences Reports Third Quarter 2026 Results

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 m

$CSTLHighAI 8/10

Castle Biosciences Reports Third Quarter 2026 Results

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

$CSTLMed

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).